Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis

Xi Guang Li, Paul Haluska, Yaw Huei Hsiang, Ajit K. Bharti, Donald W. Kufe, Leroy-Fong Liu, Eric H. Rubin

Research output: Contribution to journalArticle

37 Citations (Scopus)


Camptothecins are antineoplastic drugs that specifically target the enzyme DNA topoisomerase I. Prior work has identified a human topoisomerase I mutation, F361S, that confers resistance to camptothecin. We now demonstrate that substitutions in the 361-364 region can alter DNA cleavage/ligation by the enzyme. The defective catalysis exhibited by certain mutants likely relates to an impaired interaction with DNA, since these enzymes are more sensitive to the inhibitory effects of DNA binding ligands. Moreover, studies with peptides and fusion proteins suggest that the 361-364 region may bind DNA directly. The finding that the 361-364 region is involved in both enzyme catalysis and camptothecin resistance suggests that this region is part of the active site of human topoisomerase I and that camptothecin may interact with the enzyme at this site.

Original languageEnglish
Pages (from-to)1019-1027
Number of pages9
JournalBiochemical Pharmacology
Issue number7
Publication statusPublished - Apr 4 1997
Externally publishedYes



  • camptothecin
  • DNA binding
  • DNA cleavage
  • drug resistance
  • enzyme mutations
  • topoisomerase

ASJC Scopus subject areas

  • Pharmacology

Cite this